Drugs / ZIRITAXESTAT
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03787186 | Nov 2018 → Jan 2019 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT03515382 | Mar → Jun 2018 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT03143712 | Apr → Jun 2017 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT02179502 | Jun → Nov 2014 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03976648 | Jul 2019 → Apr 2021 | systemic sclerosis | Lakefront Biotherapeutics NV | Terminated | No outcome recorded |
| Phase 2 | NCT03798366 | Jan 2019 → May 2020 | systemic sclerosis | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 2 | NCT02738801 | Mar 2016 → May 2017 | idiopathic pulmonary fibrosis | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03711162 | Nov 2018 → Mar 2021 | idiopathic pulmonary fibrosis | Lakefront Biotherapeutics NV | Terminated | No outcome recorded |
| Phase 3 | NCT03733444 | Nov 2018 → Mar 2021 | idiopathic pulmonary fibrosis | Lakefront Biotherapeutics NV | Terminated | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZIRITAXESTAT | ChEMBL registry synonym — accepted as the source's own label CHEMBL3828074 ↗ |
| Known as | G-451990 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3828074 ↗ |
| Known as | GLPG1690 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03711162 ↗ |
| Known as | ZIRITAXESTAT (GLPG1690) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3828074 ↗ |
| Known as | ZIRITAXESTATN | ChEMBL registry synonym — accepted as the source's own label CHEMBL3828074 ↗ |
| Action | Inhibit | “GLPG1690 is a novel autotaxin inhibitor in development for the treatment of idiopathic pulmonary fibrosis (IPF).” PMID 31012984 ↗ Apr 20191“Autotaxin inhibitor” CHEMBL3828074 ↗ |
| Modality | Small molecule | — CHEMBL3828074 ↗ |
| Route | Oral | “single (20, 60, 150, 300, 600, 1000, 1500 mg) and multiple (14 days: 150 mg twice daily; 600 and 1000 mg once daily) ascending oral doses of GLPG1690” PMID 31012984 ↗ Apr 2019 |
| Target | ENPP2 | “Autotaxin inhibitor” CHEMBL3828074 ↗ |